Author details

Full Name

Peter Hersey

Affiliation

ORCID

Career Start Year

1971

Papers

347

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
35053490	Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells.	Cancers	2022
34949515	Re: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.	European Journal of Cancer	2022
34695412	Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.		2022
34503064	Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling Pathways.	Cancers	2021
33469152	Sex bias of females in survival from cancer and infections. Is X the answer?	British Journal of Cancer	2021
34220955	Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers.	Frontiers in Genetics	2021
33781756	A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma.		2021
33360855	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.	Eur J Cancer	2021
34678677	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.	European Journal of Cancer	2021
34571336	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.	Eur J Cancer	2021
32731355	Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.	Cancers (Basel)	2020
32027447	Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma?	Pigment Cell and Melanoma Research	2020
32317292	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.	J Immunother Cancer	2020
32249419	Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma.	Int J Cancer	2020
32360600	EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.		2020
31732522	A Th1/IFNÎ³ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer.	Clin Cancer Res	2020
32236593	Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive longâ¿¿term BRAF inhibition.	International Journal of Oncology	2020
32210968	Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.	Frontiers in Immunology	2020
30853334	Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy.	Trends in Immunology	2019
31797778	Shedding light on dabrafenib-induced fevers in patients with melanoma.	Lancet Oncology, The	2019
30690294	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.	Eur J Cancer	2019
29685882	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.	Clin Cancer Res	2018
30510087	Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.	Clin Cancer Res	2018
30143629	SIRT6 haploinsufficiency induces BRAF<sup>V600E</sup> melanoma cell resistance to MAPK inhibitors via IGF signalling.	Nat Commun	2018
30240750	Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma.	iScience	2018
29908991	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.	Lancet Oncol	2018
29210065	HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.	International Journal of Cancer	2018
29289977	Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report.	Cancer Immunology, Immunotherapy	2018
29599411	CD103 Tumor-Resident CD8 T Cells Are Associated with Improved Survival in Immunotherapy-NaÃ¯ve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment.	Clinical Cancer Research	2018
29283791	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.	J Clin Oncol	2018
28230439	Developing an e-learning resource for nurse airway assistants in the emergency department.	British Journal of Nursing	2017
28467829	Whole-genome landscapes of major melanoma subtypes.	Nature	2017
28591523	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.	N Engl J Med	2017
28480561	Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.	International Journal of Rheumatic Diseases	2017
28609681	Epigenetic modulation in cancer immunotherapy.	Current Opinion in Pharmacology	2017
28009056	Guidelines for the use of platelet transfusions.	Br J Haematol	2017
24868021	Acute Radiation Skin Toxicity Associated With BRAF Inhibitors.	Journal of Clinical Oncology	2016
26936398	Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.	Neoplasia	2016
27345411	Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma.	Oncogene	2016
27063195	EZH2 as a mediator of treatment resistance in melanoma.	Pigment Cell and Melanoma Research	2016
27092830	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.	JAMA	2016
26951310	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.	J Clin Oncol	2016
27863197	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.	J Clin Oncol	2016
24912396	EZH2: an emerging role in melanoma biology and strategies for targeted therapy.	Pigment Cell and Melanoma Research	2015
30190826	Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?	Melanoma Management	2015
25844720	Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-ÎºB.	PLoS ONE	2015
25836739	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.	Modern Pathology	2015
25572788	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.	Future Oncology	2015
25609064	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.	Clinical Cancer Research	2015
25477049	PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.	Pigment Cell and Melanoma Research	2015